pillbase.ru

Dupixent

Active substance: dupilumab

INJECTION, SOLUTION · DUPILUMAB 300 mg/2mL

United StatesActive

Marketing holder: Sanofi-Aventis U.S. LLC

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Дупиксент®
    раствор для подкожного введения, 150 мг/мл, 2 мл (original in Russian, GRLS)
    ЛП-№(010107)-(РГ-RU)
    Санофи Винтроп Индустрия
  • Дупиксент®
    раствор для подкожного введения, 175 мг/мл, 1.14 мл (original in Russian, GRLS)
    ЛП-005440
    Санофи Винтроп Индустрия
EU 1
  • Dupixent
    dupilumab
    EMEA/H/C/004390
    Sanofi Winthrop Industrie
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-aff8-75f6-affe-de6830d53947,01a120c5-cefa-7dbb-baf4-712d195351e8;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208e-88e1-7d70-a4b3-3b458be70373,01a1208f-fce1-7f33-854b-65e76391ec82,01a1209b-51ff-71fc-9bf7-8e3aa27d46af,01a1209b-5258-7eca-88d1-9eed75c109ab;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
0024-5915
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 0024-5915 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 0024-5915 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 0024-5915 · Verified 2026-10-09 · open in source